epirubicin has been researched along with Multiple Myeloma in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, J; Cornelissen, JJLM; Gu, W; Meng, F; Meng, H; Xu, Y; Yu, N; Zhong, Y; Zhong, Z | 1 |
| Dou, J; Guo, M; Li, M; Pan, M; Shi, F; Wang, J; Wu, D | 1 |
| Di, W; Dou, J; Gu, N; He, X; Li, M; Shi, F; Wu, S; Yang, F; Zhang, Y | 1 |
| Chen, H; Hao, QY; Huang, XJ; Liu, KY; Lu, J; Wen, L | 1 |
| Di, W; Dou, J; Gu, N; Li, M; Luo, S; Pan, M; Shi, F; Wu, S; Yang, F; Zhao, F | 1 |
| Andreesen, R; Grassinger, J; Hart, C; Hennemann, B | 1 |
| Kanz, L; Kopp, HG; Vogel, W; Weisel, KC; Yildirim, S | 1 |
| Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J | 1 |
| Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J | 1 |
| Bojko, P; Brandhorst, D; Buttkereit, U; Ebeling, P; Flasshove, M; Hense, J; Hoiczyk, M; Metz, K; Moritz, T; Nowrousian, MR; Opalka, B; Schütt, P; Seeber, S | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Andreesen, R; Blank, C; Hart, C; Hennemann, B; Krause, SW | 1 |
| Bozek, T; Corringham, R; Corringham, S; Germond, C; Goss, G; Helie, G; Koski, T; Sinoff, C; Vincent, M | 1 |
| Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Di Stasi, M; Mora, O; Petrini, M; Piccinini, L; Piva, N; Riccardi, A; Rinaldi, E; Trotti, G; Ucci, G | 1 |
| Barker, IK; Crawford, SM; Fell, AF | 1 |
| Alakhov, VY; Arjakov, SA; Batrakova, EV; Dorodnych, TY; Goncharova, ON; Kabanov, AV; Klinskii, EY; Kliushnenkova, EN; Shemchukova, OB | 1 |
| Barrow, L; Brown, R; Dyson, PG; Gibson, J; Horvath, N; Joshua, D; To, LB; Van Holst, NG | 1 |
| Giebel, S; Hołowiecki, J; Kachel, L; Kata, D; Krawczyk-Kuliś, M; Markiewicz, M; Wojciechowska, M; Wojnar, J | 1 |
| Alietti, A; Baldini, L; Colombi, M; Guffanti, A; Latargia, ML; Maiolo, AT; Vener, C | 1 |
| Arland, M; Bartsch, R; Florschütz, A; Franke, A; Höffkes, HG; Kahl, C; Lange, S; Leuner, S | 1 |
| Gola, A; Kuliczkowski, K; Sedek, K | 1 |
| Ahrenberg, P; Ala Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Jouppila, J; Palva, IP | 1 |
| Case, DC; Ervin, TJ; Gams, R; Oldham, FB; Paul, SD; Sonneborn, HL | 1 |
9 trial(s) available for epirubicin and Multiple Myeloma
| Article | Year |
|---|---|
EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Erythropoietin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Leukocyte Count; Leukocytes; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prospective Studies; Recombinant Proteins | 2009 |
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Vincristine | 2005 |
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloproliferative Disorders; Peptichemio; Prednisone; Recombinant Proteins; Vincristine | 1996 |
CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Regression Analysis; Transplantation, Autologous | 2000 |
Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma | 2000 |
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Humans; Lomustine; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2000 |
Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Therapeutic Equivalency | 2001 |
Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Epirubicin; Follow-Up Studies; Humans; Ifosfamide; Multicenter Studies as Topic; Multiple Myeloma; Prednisolone; Recurrence; Vincristine | 1990 |
14 other study(ies) available for epirubicin and Multiple Myeloma
| Article | Year |
|---|---|
CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Synergism; Epirubicin; Humans; Hyaluronan Receptors; Mice; Molecular Targeted Therapy; Multiple Myeloma; Peptide Fragments; Urokinase-Type Plasminogen Activator | 2019 |
Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Epirubicin; Female; Humans; Male; Mice; Mice, Inbred NOD; Microbubbles; Multiple Myeloma; Neoplastic Stem Cells | 2018 |
Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells.
Topics: 4-Chloro-7-nitrobenzofurazan; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Movement; Cell Survival; Cholesterol; Drug Carriers; Drug Resistance, Neoplasm; Epirubicin; Humans; Microbubbles; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Phenotype; Ultrasonic Therapy | 2016 |
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Enhancing the anti-multiple myeloma efficiency in a cancer stem cell xenograft model by conjugating the ABCG2 antibody with microbubbles for a targeted delivery of ultrasound mediated epirubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily G, Member 2; Epirubicin; Immunoconjugates; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Xenograft Model Antitumor Assays | 2017 |
Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Survival Analysis; Syndecan-1; Transplantation, Autologous; Young Adult | 2009 |
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation | 2011 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2007 |
Bi-weekly vincristine, epirubicin and methylprednisolone in alkylator-refractory multiple myeloma.
Topics: Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance; Epirubicin; Feasibility Studies; Female; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Vincristine | 1994 |
Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Doxorubicin; Epirubicin; Humans; Infusion Pumps; Kinetics; Multiple Myeloma; Naphthacenes; Regression Analysis; Reproducibility of Results | 1996 |
Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity.
Topics: Animals; Antibiotics, Antineoplastic; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Epirubicin; Female; Leukemia P388; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Micelles; Multiple Myeloma; Neoplasm Transplantation; Poloxalene | 1996 |
Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.
Topics: Adult; Bone Marrow; Carmustine; Drug Resistance; Epirubicin; Humans; Immunoglobulins; Melphalan; Middle Aged; Multiple Myeloma; Thymidine; Tritium; Tumor Cells, Cultured | 1992 |
Phase I-II study of epirubicin in multiple myeloma.
Topics: Aged; Aged, 80 and over; Drug Evaluation; Epirubicin; Heart; Humans; Middle Aged; Multiple Myeloma | 1988 |